Harpoon Therapeutics Inc

Harpoon Therapeutics, Inc. is a clinical-stage immunotherapy company, which engages in the development of antibodies. It focuses on the research of novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. The firm utilizes its proprietary Tri-specific T cell Activating Construct platform to create a pipeline of novel TriTACs for the treatment of solid tumors and hematologic malignancies. The company was founded by Patrick A. Baeuerle, Luke B. Evnin, and Jeanmarie Guenot on March 19, 2015 and is headquartered in South San Francisco, CA.

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Harpoon Therapeutics is a clinical-stage immunotherapy company developing a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. T cell engagers are engineered proteins that direct a patient’s own T cells to kill target cells that express specific proteins, or antigens, carried by the target cells. Using its proprietary Tri-specific T cell Activating Construct? (TriTAC), platform, Harpoon is developing a pipeline of novel T cell engagers, or TriTACs, initially focused on the treatment of solid tumors and hematologic malignancies.  Harpoon's first drug candidate, HPN424, is currently in Phase 1 clinical trial as a treatment for prostate cancer.

Harpoon Therapeutics Inc shares surged as much as 40% in pre-market trading on Monday after the clinical-stage immunotherapy company announced that its lung cancer drug (HPN328) showed "promising" antitumor activity and tolerability profile in a Phase 1/2 clinical trial.  Harpoon said the preliminary response data for evaluable patients treated in one milligram priming dose cohorts showed confirmed response rate of 35% across all tumor types.

Harpoon Therapeutics stock soars on ‘promising' lung cancer drug results

SOUTH SAN FRANCISCO, Calif., Oct. 23, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP) (the “Company”), a clinical-stage immunotherapy company developing novel T cell engagers, today announced that it has entered into a securities purchase agreement for a private placement in public equity (“PIPE”) financing that is expected to result in upfront gross proceeds of approximately $100 million, with up to an additional approximately $50 million of gross proceeds upon cash exercise of warrants, before deducting placement agent fees and offering expenses. The PIPE financing was led by a leading biotechnology investor associated with one of the largest alternative asset managers, with participation from new and existing investors including Soleus Capital, Commodore Capital, New Leaf Venture Partners, Cormorant Asset Management, RA Capital Management, Invus, Surveyor Capital (a Citadel company), K2 HealthVentures, Ally Bridge Group, Lion Point Capital, and a large mutual fund.

Harpoon Therapeutics Announces Up to $150 Million Private Placement

SOUTH SAN FRANCISCO, Calif., Oct. 21, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced the updated interim monotherapy data from its Phase 1/2 clinical trial evaluating HPN328 in small cell lung cancer (SCLC) and other neuroendocrine tumor types in a poster at the European Society of Medical Oncology Congress (ESMO) 2023. HPN328 targets delta-like ligand 3 (DLL3) and is derived from Harpoon's proprietary Tri-specific T cell Activating Construct (TriTAC®) platform designed to recruit a patient's own immune cells to kill tumor cells.

Harpoon Therapeutics Announces Updated Interim Tolerability and Response Data from Phase 1/2 Clinical Trial of T Cell Engager HPN328 at ESMO Congress 2023

SOUTH SAN FRANCISCO, Calif., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced that it will host a live webcast at 8:00 a.m. ET / 2:00 p.m. CEST on Monday, October 23, 2023 to review interim monotherapy data from its Phase 1/2 clinical trial evaluating HPN328 in small cell lung cancer (SCLC) and other neuroendocrine neoplasms (NEN) presented at the European Society of Medical Oncology Congress (ESMO) 2023.

Harpoon Therapeutics to Host Webcast Reviewing HPN328 Interim Data Presented at ESMO Congress 2023 on October 23, 2023

SOUTH SAN FRANCISCO, Calif., Oct. 09, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced that it will present interim monotherapy data from its Phase 1/2 clinical trial evaluating HPN328 in small cell lung cancer (SCLC) and other neuroendocrine neoplasms (NEN) in a poster presentation at the European Society of Medical Oncology Congress (ESMO) 2023 taking place in Madrid, Spain from October 20-24, 2023. HPN328 targets delta-like ligand 3 (DLL3) and is derived from Harpoon's proprietary Tri-specific T cell Activating Construct (TriTAC®) platform designed to recruit a patient's own immune cells to kill tumor cells.

Harpoon Therapeutics to Present Interim Tolerability and Response Data from Phase 1/2 Clinical Trial of T Cell Engager HPN328 at ESMO Congress 2023

Target dose of 12 mg demonstrates robust early activity and manageable tolerability profile: – 63% ORR, 16% cytokine release syndrome (CRS), No ICANS –

Harpoon Therapeutics Presents HPN217 Interim Phase 1 Data at the IMS Annual Meeting

SOUTH SAN FRANCISCO, Calif., Sept. 15, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immuno-oncology company developing novel T cell engagers, today announced dosing of the first patients with small cell lung cancer (SCLC) in an ongoing Phase 1/2 trial of HPN328, a DLL3 targeting TriTAC®, in combination with atezolizumab (Tecentriq®). Harpoon previously entered a Master Clinical Supply Agreement with F. Hoffmann-La Roche for the supply of atezolizumab. Under this agreement, Harpoon is the sponsor of the trial and Roche will supply atezolizumab. This announcement is being made in conjunction with Harpoon's investor event, “DLL3 Market Opportunity and KOL Discussion of HPN328,” held virtually and in person today in New York beginning at 8 a.m. ET.

Harpoon Therapeutics Announces First Patients with Small Cell Lung Cancer Dosed in HPN328 Combination Cohort

SOUTH SAN FRANCISCO, Calif., Sept. 13, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immuno-oncology company developing novel T cell engagers, announced today that AbbVie has notified the company that it will not exercise the exclusive license option of the parties' Development and Option Agreement in connection with Harpoon's HPN217 program, which targets B cell maturation antigen, or BCMA. ​The Agreement, which will terminate effective October 12, 2023, granted AbbVie an option to a worldwide, exclusive license to the HPN217 program. The program has been and will remain exclusively owned by Harpoon, and the company plans to complete the ongoing Phase 1 clinical trial with data to support the next phase of development.

Harpoon Therapeutics Provides an Update on the HPN217 Development and Option Agreement with AbbVie

SOUTH SAN FRANCISCO, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immuno-oncology company developing novel T cell engagers, today announced abstract acceptance and a poster presentation of preliminary data (up to and including 12mg cohorts) from the dose escalation portion of the Phase 1 study of HPN217 in patients with relapsed/refractory multiple myeloma. The presentation will take place at the upcoming 20th International Myeloma Society (IMS) Annual Meeting being held September 27-30, 2023 in Athens, Greece.

Harpoon Therapeutics Abstract for HPN217 Accepted for Poster Presentation at the 20th International Myeloma Society Annual Meeting

KOLs to provide insight and discussion of HPN328 targeting SCLC, NEPC and other neuroendocrine tumors Abstract with HPN328 interim data accepted for poster presentation at the European Society for Medical Oncology (ESMO) being held October 20-24, 2023 SOUTH SAN FRANCISCO, Calif., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immuno-oncology company developing novel T cell engagers, today announced that management will host an in-person event “DLL3 Market Opportunity and KOL Discussion of HPN328”, in New York on September 15, 2023 from 8:00 to 9:30 a.m.

Harpoon Therapeutics to Host KOL Event in Person and via Webcast on September 15, 2023

SOUTH SAN FRANCISCO, Calif., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced that management will participate in two upcoming investor conferences in September.

Harpoon Therapeutics to Participate in Two Upcoming Investor Conferences in September

Harpoon Therapeutics, Inc. (HARP) came out with quarterly earnings of $0.03 per share, beating the Zacks Consensus Estimate of a loss of $0.43 per share. This compares to loss of $0.53 per share a year ago.

Harpoon Therapeutics, Inc. (HARP) Beats Q2 Earnings and Revenue Estimates

Abstracts for HPN217 and HPN328 accepted for presentations at the International Myeloma Society (IMS) Annual Meeting and the European Society for Medical Oncology (ESMO) in the fall

Harpoon Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update

SOUTH SAN FRANCISCO, Calif., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced that management will participate in two upcoming investor conferences:

Harpoon Therapeutics to Participate in Two Upcoming Investor Conferences in August

SOUTH SAN FRANCISCO, Calif., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immuno-oncology company developing novel T cell engagers, today announced the appointment of Haibo Wang as Senior Vice President of Business Development. Mr. Wang brings 15 years of biopharma business development, finance, and mergers and acquisitions (M&A) transaction experience to Harpoon.

Harpoon Therapeutics Appoints Haibo Wang as Senior Vice President of Business Development

Biopharma executive with more than 20 years of global corporate, business development, and commercial strategy experience to join Replicate leadership team SAN DIEGO , July 10, 2023 /PRNewswire/ -- Replicate Bioscience, a company pioneering novel self-replicating RNA (srRNA) technology for use in infectious disease, oncology, autoimmune disease, and more, announced today that it has appointed Rachael Lester as its Chief Business Officer. Ms. Lester, who has more than 20 years of experience as a senior executive in the biopharmaceutical industry, will be responsible for leading corporate strategy, business development, portfolio strategy, and new product planning.

Replicate Bioscience Appoints Rachael Lester as Chief Business Officer

SOUTH SAN FRANCISCO, Calif., June 27, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immuno-oncology company developing novel T cell engagers, today announced the completion of planned patient enrollment in the Phase 1 dose escalation study evaluating the safety, tolerability, and pharmacokinetics of HPN217 in patients with relapsed/refractory multiple myeloma. Additional patients currently in screening will also be allowed to enroll.

Harpoon Therapeutics Announces Completion of Planned Patient Enrollment in Phase 1 Study of HPN217 in Relapsed/Refractory Multiple Myeloma

Bionano Genomics

Nauticus Robotics Inc

With investors looking for growth wherever they can find it, it's a good time to look at penny stocks to watch in 2023. Granted, penny stocks carry a higher risk than blue-chip stocks, but they also carry the potential for outsized returns.

3 Penny Stocks with Multibagger Potential for the Second Half of 2023

Harpoon Therapeutics, Inc. (HARP) came out with a quarterly loss of $0.31 per share versus the Zacks Consensus Estimate of a loss of $0.42. This compares to loss of $0.62 per share a year ago.

Harpoon Therapeutics, Inc. (HARP) Reports Q1 Loss, Lags Revenue Estimates

Enrollment for HPN217 (BCMA) and HPN328 (DLL3) remain on track, with data updates and selection of recommended Phase 2 doses for both ongoing clinical programs planned in 2023

Harpoon Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update

SOUTH SAN FRANCISCO, Calif., April 18, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immuno-oncology company developing novel T cell engagers, today presented preclinical data for two of its key clinical programs, HPN328 and HPN217, in three poster presentations at the American Association for Cancer Research (AACR) Annual Meeting being held in Orlando, Fla., April 14-19, 2023. HPN217 targets B-cell maturation antigen (BCMA) and is based on Harpoon's proprietary Tri-specific T cell Activating Construct (TriTAC®) platform designed to recruit a patient's own immune cells to kill tumor cells. HPN328 is Harpoon's half-life extended TriTAC that targets delta-like canonical Notch ligand 3 (DLL3).

Harpoon Therapeutics Presents Preclinical Results for Novel T Cell Engagers HPN217 and HPN328 at AACR 2023

Results support further investigation of two new ProTriTAC™ protease-activated T cell engager development candidates, with demonstrated therapeutic potential in a broad range of TROP2- and integrin-beta6 (ITGB6)-expressing solid tumors Results support further investigation of two new ProTriTAC™ protease-activated T cell engager development candidates, with demonstrated therapeutic potential in a broad range of TROP2- and integrin-beta6 (ITGB6)-expressing solid tumors

Harpoon Therapeutics Presents Data for New ProTriTAC™ Development Candidates in TROP2- and ITGB6-expressing Solid Tumors at AACR 2023

SOUTH SAN FRANCISCO, Calif., April 10, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immuno-oncology company developing novel T cell engagers, today announced that Julie Eastland, President and Chief Executive Officer, and Luke Walker, M.D., Chief Medical Officer, will participate in a panel and one-on-one meetings with institutional investors at the virtual Canaccord Horizons in Oncology Conference on April 20, 2023. The panel titled “T-Cell Engagers Coming of Age” will take place from 11:00-11:45 a.m. ET.

Harpoon Therapeutics to Participate in the Canaccord Horizons in Oncology Conference

HPN217 (BCMA) and HPN328 (DLL3) enrollment on track, with data updates and selection of recommended Phase 2 doses for both active clinical programs planned in 2023

Harpoon Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

SOUTH SAN FRANCISCO, Calif., March 27, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP) (the “Company”), a clinical-stage immuno-oncology company developing novel T cell engagers, today announced that it has closed a private placement of redeemable preferred stock and warrants to purchase common stock to certain institutional and other accredited investors for aggregate gross proceeds to the Company of $25 million, before deducting offering expenses, which does not include any proceeds that may be received upon exercise of the warrants.

News for Harpoon Therapeutics Inc Stock (HARP)